The FairTax Act of 2025 would repeal federal income tax, payroll taxes (Social Security and Medicare), and estate and gift taxes, replacing them with a national sales tax. It would impose a 23% tax on the final consumption of goods and services in 2027, with rates adjusting based on federal tax rates. The bill includes a monthly rebate for qualifying families based on the poverty level to offset the tax burden on lower-income households. It would establish a cooperative tax administration system between federal and state governments, with states collecting the tax under certain conditions. The tax would sunset if the 16th Amendment (which allows for income taxes) is not repealed within 7 years of enactment.
This bill prohibits doctors from performing abortions based solely on a Down syndrome diagnosis. It requires providers to ask patients about such diagnoses before an abortion and inform them of the ban. Violations could result in criminal penalties (up to 5 years in prison) or civil lawsuits seeking damages for the patient or family. The law applies to all abortions performed in the U.S. or transported across state lines for this specific purpose. It does not restrict other abortion procedures or create a new right to abortion.
Protecting Life from Chemical Abortions Act This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be program-certified in order to dispense mifepristone. The modifications allow certified retail pharmacies to dispense mifepristone pursuant to prescriptions that are written by certified prescribers. The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention. The bill also generally prohibits the declaration of a public health emergency with respect to abortions.
HR 3044, the "No Vaccine Mandates in Higher Education Act," prohibits federal funding from being provided to colleges and universities that require students or staff to receive a COVID-19 vaccine for enrollment, employment, or access to services. This directly affects institutions of higher education receiving federal funds, such as those participating in student aid programs. The bill's key mechanism is withholding federal funds from any institution enforcing such vaccine mandates, as defined under the Higher Education Act of 1965. The law focuses solely on vaccine requirements, not other health or safety policies.
HR 2387, the "No Harm Act," prohibits federal funding for certain medical treatments for minors that the bill defines as "sex-trait altering treatments," including puberty blockers, hormone therapy, and gender reassignment surgeries (except for specific medical conditions like disorders of sex development). The bill directly affects minors receiving such care, healthcare providers, medical institutions, and schools, requiring parental consent for any treatment and banning federal funds for facilities or schools that provide these treatments without parental approval. Key provisions include banning federal funds for any promotion or facilitation of these treatments, mandating a 72-hour parental consultation period before treatment, and creating civil lawsuits for violations. The bill defines "sex" as biological sex at birth and "gender" as social aspects, excluding only treatments for medically verified conditions.
The Ensuring Medicaid Eligibility Act of 2025 prohibits the implementation of a 2024 rule that would have streamlined Medicaid application and enrollment processes. It requires states to verify U.S. citizenship or immigration status before enrolling individuals in Medicaid and mandates quarterly verification of income-based eligibility for those relying on income calculations. The bill also blocks federal funding for Medicaid coverage for certain non-citizens, including parolees, Temporary Protected Status (TPS) recipients, Deferred Action for Childhood Arrivals (DACA) recipients, asylum seekers, and individuals granted withholding of removal. These provisions directly affect non-citizen Medicaid applicants and require states to adjust enrollment and verification procedures.
HR 1476, the PLASMA Act, adjusts discount rates for plasma-derived drugs under Medicare Part D starting in 2026. It sets gradually decreasing discount percentages (from 99% down to 90% by 2030) for these specific drugs when beneficiaries reach their annual out-of-pocket spending threshold. The bill directly affects Medicare Part D beneficiaries using plasma-derived biological products (drugs made from human blood or plasma) and the manufacturers of those drugs. Certain drugs for low-income subsidy beneficiaries and small manufacturers are excluded from these discount provisions. The law phases in these changes over several years to align with existing Medicare Part D cost-sharing rules.
This bill prohibits U.S. foreign aid from funding any foreign government or organization that provides, promotes, or facilitates abortions under most circumstances. It blocks funding to foreign entities performing abortions, offering abortion referrals, promoting abortion services, or funding related research, with exceptions only for pregnancies resulting from rape or incest (requiring documented proof like police reports). Foreign governments and organizations receiving U.S. aid must certify compliance annually, and violations risk losing future funding, repayment of misused funds, or penalties. The policy directly affects U.S. foreign assistance programs targeting global health and development, excluding only rape/incest cases with required documentation.
This bill prohibits federal funding for any state, local, tribal, or private entity operating an injection center that violates the Controlled Substances Act's Crack House Statute (21 U.S.C. 856), which bans drug use in buildings. It directly affects organizations running facilities where illegal drug use occurs, cutting off all federal grants or programs from such entities. The law does not create new drug offenses but withholds existing federal funds from facilities operating in violation of current law. It applies broadly to all federal funding streams, not just specific programs.
This bill requires abortion providers to give patients a consent form outlining disposal options for fetal remains (taking the remains or transferring them to interment/cremation services). Providers must arrange interment or cremation within 7 days if patients release remains, and face civil penalties up to $50,000 or criminal charges for noncompliance. It mandates annual reporting by providers on abortion procedures, gestational age, and disposal methods, with the Secretary submitting a separate report to Congress. The bill directly affects abortion providers and patients receiving abortion care, adding handling and reporting requirements for fetal remains without changing abortion access or medical procedures.
